Daxor Announces Florida Cardiovascular Institute of Tampa, FL Acquires BVA-100 Blood Volume Analyzer
Posted on: Thursday, 25 January 2007, 09:01 CST
Daxor Corporation (AMEX: DXR), a medical instrumentation and biotechnology company, today announced the receipt of a signed trial agreement from the Florida Cardiovascular Institute of Tampa, Florida.
The Florida Cardiovascular Institute (FCI) provides state-of-the-art, compassionate health care ranging from preventative medicine to the treatment of the most complex heart and vascular diseases. As the region's only private cardiology practice offering a blood volume analysis (BVA), FCI reaffirms its commitment to providing the highest quality health services available. Through the years, FCI Heart Center has earned its highly regarded reputation in the community by integrating the latest technology and most effective techniques into treatment so their patients can lead healthier and more active lives.
"We are extremely excited to begin working with FCI, especially as this will be Daxor's first BVA-100 within a private practice setting in Florida," noted John Reyes-Guerra, Daxor's Vice President of Sales and Marketing. Mr. Reyes-Guerra also noted that, "FCI has been an innovator in cardiovascular disease management and treatment through their dedication to patient-oriented research through the Florida Cardiovascular Institute and Research Foundation and their relationships with leading academic and community institutions committed to improving patient care."
The Daxor Blood Volume Analyzer BVA-100 permits FCI to offer its patients along with area physicians treating various heart and vascular diseases to accurately measure and then treat a patient's volume derangement. Previous published studies in heart failure have demonstrated that patients who have had their blood volume diagnosed and treated to a normal blood volume by a BVA have significant improved outcomes than patients who remain "volume overloaded."
Daxor Corporation manufactures and markets the BVA-100, a semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website www.Daxor.com.
Contact Information: Stephen Feldschuh 212-330-8515 Chief Operating Officer Contact via http://www.marketwire.com/mw/emailprcntct?id=F3F808CE8632D3C9 Diane Meegan 212-330-8512 Investor Relations Contact via http://www.marketwire.com/mw/emailprcntct?id=3FDC4D0ADE6CD0DD
SOURCE: Daxor Corp.
Source: MARKET WIRE
Related Articles
- Improving Treatment Of Patients With Heart Attack
- Crowded Emergency Clinics Pose Greater Risks For Patients With Heart Attacks
- Studies Indicate Exercise Training Could Provide Some Benefit For Patients With Heart Failure
- Low blood pressure aids dialysis patients
- Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
- Lipitor 80 Mg Reduced the Risk of Heart Attack and Stroke in Patients With Heart Disease, Type 2 Diabetes and Chronic Kidney Disease
- Cleviprex(TM) Reduces and Controls Acutely Elevated Blood Pressure in Elderly Patients, According to New Analysis From VELOCITY Trial
- CoGenesys Initiates Phase 1-2 Clinical Trial of Cardeva in Patients With Heart Failure
- US patients with heart failure have better short-term survival rates than Canadian patients
- Amgen Announces Initiation of Phase 3 Trial to Evaluate the Impact of Treating Anemia With Darbepoetin Alfa in Patients With Heart Failure to Reduce Mortality and Hospitalization
 |
 |
User Comments (0)
RSS Feeds